Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06470295 · ClinicalTrials.gov registry record · Early Phase 1
Effect of C-peptide on Hypoglycemic Counterregulation
A Early Phase 1 study of Type 1 Diabetes and Hypoglycemia, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06470295: Recruiting Early Phase 1 study of Type 1 Diabetes and Hypoglycemia, sponsored by University of Cincinnati.
NCT06470295 is a Early Phase 1 study of Type 1 Diabetes and Hypoglycemia that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 38 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06470295, a Early Phase 1 study of Type 1 Diabetes and Hypoglycemia, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.
Primary Outcome
from plasma
Conditions Studied
Interventions
- OTHER Saline
- BIOLOGICAL C-peptide
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2028-01-01 |
| Phase | Early Phase 1 |
What NCT06470295 shows while recruiting
NCT06470295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT06470295 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06470295 about?
NCT06470295 is a clinical study titled "Effect of C-peptide on Hypoglycemic Counterregulation". Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose ...
What is the current status of trial NCT06470295?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2024-06-01. Estimated completion is 2028-01-01.
What conditions does trial NCT06470295 study?
This clinical trial studies the following conditions: Type 1 Diabetes, Hypoglycemia.
What interventions are being tested in trial NCT06470295?
The interventions under investigation include: Saline (OTHER), C-peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT06470295?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06470295 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06470295's enrollment target sits among peer trials
38 111th of 198 higher than 86 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
RECRUITING · Early Phase 1
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Adrenergic System in Islet Transplantation
ACTIVE NOT RECRUITING · Early Phase 1
-
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
COMPLETED · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
-
Early Markers of Disease and Response to Therapy
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI